Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: avandia Clear all
Completed Phase 3 Interventional

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

NCT00399711
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

NCT00123643
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, glyburide
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 30, 2026, 4:05 PM EDT
Terminated Not applicable Interventional

Rosiglitazone-Induced Weight Gain

NCT00225225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, dietary recommendation for weight maintenance
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Rosiglitazone, Normal saline 0.9%, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 30, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

NCT00006071
View directory record Official record
Conditions
Hypercholesterolemia, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Insulin, Neurogenetics and Memory in Alzheimer's Disease

NCT00018382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
rosiglitazone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

NCT00006493
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Rosiglitazone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

NCT00182052
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Prostate Cancer
Interventions
Rosiglitazone, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance

NCT00618072
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Obesity
Interventions
metformin and rosiglitazone
Drug
Lead sponsor
New York Medical College
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 30, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

NCT00612066
View directory record Official record
Conditions
Cushing's Disease
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

NCT00549874
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Rosiglitazone, Glyburide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Ann Arbor, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Oct 30, 2026, 4:05 PM EDT
Not listed Phase 2 Interventional

Rosiglitazone Effects on Cognition for Adults in Later Life

NCT00242593
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Rosiglitazone
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Seattle/Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

NCT00577590
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Metformin, Rosiglitazone, Lovaza
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

NCT00110851
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, metformin, PN2034
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
21 Years to 72 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Waterbury, Connecticut • DeLand, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Vascular Diseases
Interventions
Rosiglitazone, Pioglitazone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 30, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT00252499
View directory record Official record
Conditions
Fatty Liver, Insulin Resistance
Interventions
rosiglitazone, fenofibrate, placebo for rosiglitazone, placebo for fenofibrate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone

NCT00746174
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

The Impact of Obesity and Obesity Treatments on Breast Cancer

NCT00933309
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Avandamet
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 30, 2026, 4:05 PM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

NCT00381238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00135330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide, rosiglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

NCT00099918
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 30, 2026, 4:05 PM EDT